Kidney disease characteristics and diagnoses in patients without diabetes by study.
| Characteristics . | FIND-CKD (N = 1584) . | DAPA-CKD (N = 1398) . | EMPA-KIDNEY (N = 3570) . |
|---|---|---|---|
| eGFR (ml/min/1.73 m2), mean (SD) | 46.70 (16.1) | 41.7 (11.7) | 38.7 (15.4) |
| eGFR category (ml/min/1.73 m2), n (%)a | |||
| <30 | 241 (15.2) | 223 (16.0) | 1132 (32.0) |
| 30–<45 | 603 (38.1) | 659 (47.1) | 1546 (43.0) |
| 45–<60 | 423 (26.7) | 410 (29.3) | 892 (25.0) |
| ≥60 | 317 (20.0) | 106 (7.6) | |
| UACR (mg/g), median (IQR) | 818.9 (577.4–1244.0) | 861 | 461 (128–1117) |
| UACR category (mg/g), n (%) | |||
| <30 (stage A1) | 0 (0) | 0 (0) | 683 (19) |
| 30–300 (stage A2) | 63 (4.0) | 136 (9.7) | 921 (26) |
| ≥300 (stage A3) | 1521 (96.0) | 1262 (90.3) | 1966 (55) |
| Kidney disease aetiology, n (%) | |||
| Hypertensive/ischemic nephropathy | 460 (29.0) | 494 (35.3) | 1044 (29.2) |
| Any glomerular disease | 903 (57.0) | 598 (42.8) | 1497 (41.9) |
| IgAN | 417 (26.3) | 232 (16.6) | 758 (21.2) |
| FSGS | 215 (13.6) | 93 (6.7) | 161 (4.5) |
| Membranous nephropathy | 91 (5.7) | 33 (2.4) | 83 (2.3) |
| Glomerulonephritis minimal lesion | 7 (0.4) | 9 (0.6) | 10 (0.3) |
| Other glomerular disease | 154 (9.7) | 231 (16.5) | 485 (13.6) |
| Other | 57 (3.6) | 139 (9.9) | 605 (16.9) |
| Tubulointerstitial disease (including obstructive) | 8 (0.5) | 117 (8.4) | 367 (10.3) |
| Unknown | 164 (10.4) | 167 (11.9) | 424 (11.9) |
| Prior kidney biopsy, n (%) | 787 (49.7) | 500 (35.8) | 1508 (42.2) |
| Characteristics . | FIND-CKD (N = 1584) . | DAPA-CKD (N = 1398) . | EMPA-KIDNEY (N = 3570) . |
|---|---|---|---|
| eGFR (ml/min/1.73 m2), mean (SD) | 46.70 (16.1) | 41.7 (11.7) | 38.7 (15.4) |
| eGFR category (ml/min/1.73 m2), n (%)a | |||
| <30 | 241 (15.2) | 223 (16.0) | 1132 (32.0) |
| 30–<45 | 603 (38.1) | 659 (47.1) | 1546 (43.0) |
| 45–<60 | 423 (26.7) | 410 (29.3) | 892 (25.0) |
| ≥60 | 317 (20.0) | 106 (7.6) | |
| UACR (mg/g), median (IQR) | 818.9 (577.4–1244.0) | 861 | 461 (128–1117) |
| UACR category (mg/g), n (%) | |||
| <30 (stage A1) | 0 (0) | 0 (0) | 683 (19) |
| 30–300 (stage A2) | 63 (4.0) | 136 (9.7) | 921 (26) |
| ≥300 (stage A3) | 1521 (96.0) | 1262 (90.3) | 1966 (55) |
| Kidney disease aetiology, n (%) | |||
| Hypertensive/ischemic nephropathy | 460 (29.0) | 494 (35.3) | 1044 (29.2) |
| Any glomerular disease | 903 (57.0) | 598 (42.8) | 1497 (41.9) |
| IgAN | 417 (26.3) | 232 (16.6) | 758 (21.2) |
| FSGS | 215 (13.6) | 93 (6.7) | 161 (4.5) |
| Membranous nephropathy | 91 (5.7) | 33 (2.4) | 83 (2.3) |
| Glomerulonephritis minimal lesion | 7 (0.4) | 9 (0.6) | 10 (0.3) |
| Other glomerular disease | 154 (9.7) | 231 (16.5) | 485 (13.6) |
| Other | 57 (3.6) | 139 (9.9) | 605 (16.9) |
| Tubulointerstitial disease (including obstructive) | 8 (0.5) | 117 (8.4) | 367 (10.3) |
| Unknown | 164 (10.4) | 167 (11.9) | 424 (11.9) |
| Prior kidney biopsy, n (%) | 787 (49.7) | 500 (35.8) | 1508 (42.2) |
Calculated by the CKD-EPI equation.
FSGS: focal segmental glomerulosclerosis.
Sources: Wheeler et al. [37], EMPA-KIDNEY Collaborative Group [38].
Kidney disease characteristics and diagnoses in patients without diabetes by study.
| Characteristics . | FIND-CKD (N = 1584) . | DAPA-CKD (N = 1398) . | EMPA-KIDNEY (N = 3570) . |
|---|---|---|---|
| eGFR (ml/min/1.73 m2), mean (SD) | 46.70 (16.1) | 41.7 (11.7) | 38.7 (15.4) |
| eGFR category (ml/min/1.73 m2), n (%)a | |||
| <30 | 241 (15.2) | 223 (16.0) | 1132 (32.0) |
| 30–<45 | 603 (38.1) | 659 (47.1) | 1546 (43.0) |
| 45–<60 | 423 (26.7) | 410 (29.3) | 892 (25.0) |
| ≥60 | 317 (20.0) | 106 (7.6) | |
| UACR (mg/g), median (IQR) | 818.9 (577.4–1244.0) | 861 | 461 (128–1117) |
| UACR category (mg/g), n (%) | |||
| <30 (stage A1) | 0 (0) | 0 (0) | 683 (19) |
| 30–300 (stage A2) | 63 (4.0) | 136 (9.7) | 921 (26) |
| ≥300 (stage A3) | 1521 (96.0) | 1262 (90.3) | 1966 (55) |
| Kidney disease aetiology, n (%) | |||
| Hypertensive/ischemic nephropathy | 460 (29.0) | 494 (35.3) | 1044 (29.2) |
| Any glomerular disease | 903 (57.0) | 598 (42.8) | 1497 (41.9) |
| IgAN | 417 (26.3) | 232 (16.6) | 758 (21.2) |
| FSGS | 215 (13.6) | 93 (6.7) | 161 (4.5) |
| Membranous nephropathy | 91 (5.7) | 33 (2.4) | 83 (2.3) |
| Glomerulonephritis minimal lesion | 7 (0.4) | 9 (0.6) | 10 (0.3) |
| Other glomerular disease | 154 (9.7) | 231 (16.5) | 485 (13.6) |
| Other | 57 (3.6) | 139 (9.9) | 605 (16.9) |
| Tubulointerstitial disease (including obstructive) | 8 (0.5) | 117 (8.4) | 367 (10.3) |
| Unknown | 164 (10.4) | 167 (11.9) | 424 (11.9) |
| Prior kidney biopsy, n (%) | 787 (49.7) | 500 (35.8) | 1508 (42.2) |
| Characteristics . | FIND-CKD (N = 1584) . | DAPA-CKD (N = 1398) . | EMPA-KIDNEY (N = 3570) . |
|---|---|---|---|
| eGFR (ml/min/1.73 m2), mean (SD) | 46.70 (16.1) | 41.7 (11.7) | 38.7 (15.4) |
| eGFR category (ml/min/1.73 m2), n (%)a | |||
| <30 | 241 (15.2) | 223 (16.0) | 1132 (32.0) |
| 30–<45 | 603 (38.1) | 659 (47.1) | 1546 (43.0) |
| 45–<60 | 423 (26.7) | 410 (29.3) | 892 (25.0) |
| ≥60 | 317 (20.0) | 106 (7.6) | |
| UACR (mg/g), median (IQR) | 818.9 (577.4–1244.0) | 861 | 461 (128–1117) |
| UACR category (mg/g), n (%) | |||
| <30 (stage A1) | 0 (0) | 0 (0) | 683 (19) |
| 30–300 (stage A2) | 63 (4.0) | 136 (9.7) | 921 (26) |
| ≥300 (stage A3) | 1521 (96.0) | 1262 (90.3) | 1966 (55) |
| Kidney disease aetiology, n (%) | |||
| Hypertensive/ischemic nephropathy | 460 (29.0) | 494 (35.3) | 1044 (29.2) |
| Any glomerular disease | 903 (57.0) | 598 (42.8) | 1497 (41.9) |
| IgAN | 417 (26.3) | 232 (16.6) | 758 (21.2) |
| FSGS | 215 (13.6) | 93 (6.7) | 161 (4.5) |
| Membranous nephropathy | 91 (5.7) | 33 (2.4) | 83 (2.3) |
| Glomerulonephritis minimal lesion | 7 (0.4) | 9 (0.6) | 10 (0.3) |
| Other glomerular disease | 154 (9.7) | 231 (16.5) | 485 (13.6) |
| Other | 57 (3.6) | 139 (9.9) | 605 (16.9) |
| Tubulointerstitial disease (including obstructive) | 8 (0.5) | 117 (8.4) | 367 (10.3) |
| Unknown | 164 (10.4) | 167 (11.9) | 424 (11.9) |
| Prior kidney biopsy, n (%) | 787 (49.7) | 500 (35.8) | 1508 (42.2) |
Calculated by the CKD-EPI equation.
FSGS: focal segmental glomerulosclerosis.
Sources: Wheeler et al. [37], EMPA-KIDNEY Collaborative Group [38].
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
